Elevated serum transaminase levels resulting from concomitant use of rosuvastatin and amiodarone

American Journal of Health-System Pharmacy

Volumn 64, Issue 17, 2007, Pages 1818-1821

  Merz, Tonja ^a   Fuller, Stephen H ^b  

^a WINGATE UNIVERSITY   (United States)

^b CAMPBELL UNIVERSITY   (United States)

Author keywords

Amiodarone; Antilipemic agents; Cardiac drugs; Drug interactions; Drugs, adverse reactions; Geriatrics; Rosuvastatin

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALENDRONIC ACID; AMIODARONE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; FUROSEMIDE; GEMFIBROZIL; GLIBENCLAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVOTHYROXINE; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; METOPROLOL; ROSUVASTATIN; TRIACYLGLYCEROL; ANTIARRHYTHMIC AGENT; FLUOROBENZENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; AORTA STENOSIS; AORTA SURGERY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG WITHDRAWAL; ECHOGRAPHY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; LABORATORY TEST; LIVER FUNCTION TEST; PRIORITY JOURNAL; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; AORTA VALVE; AORTA VALVE STENOSIS; BLOOD; DRUG INTERACTION; TRANSPLANTATION;

AGED; ALANINE TRANSAMINASE; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; AORTIC VALVE; AORTIC VALVE STENOSIS; ASPARTATE AMINOTRANSFERASES; DRUG INTERACTIONS; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; PYRIMIDINES; SULFONAMIDES;

EID: 34848923693     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp060305     Document Type: Article

References (10)

1. Drug Topics. Top 200 brand-name drugs by units in 2005. www.drugtopics. com/drugtopics/data/articlestandard/drugtopics/102006/311294/article.pdf (accessed 2007 Jun 1).
2. Pasternak RC, Smith SC Jr, Bairey-Merz CN et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002; 40:567-72.
3. Pacerone (amiodarone hydrochloride) package insert. Minneapolis, MN: Upsher-Smith Laboratories, Inc.; 2006 Jan.
4. Ricaurte B, Guirguis A, Taylor HC et al. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother. 2006; 40:753-7.
5. Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110:227-39. [Erratum, Circulation. 2004; 110:763.]
6. Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleve Clin J Med. 2004; 71:58-62.
7. Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45.
8. Crestor (rosuvastatin calcium) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2005 Dec.
9. Sniderman AD. Is there value in liver function test and creatine phosphokinase monitoring with statin use? Am J Cardiol. 2004; 94(suppl 9A):30F-4F.
10. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002; 41:343-70.